论文部分内容阅读
目的:观察射干麻黄汤联合孟鲁司特治疗咳嗽变异性哮喘(CVA)的临床疗效及对血清炎症因子水平的影响。方法:将76例CVA患者随机分为2组各38例。对照组予以孟鲁司特咀嚼片口服,治疗组在对照组的基础上加用射干麻黄汤内服,2组疗程均为12周。观察比较2组临床疗效,并检测治疗前后血清超敏C-反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)水平变化。结果:总有效率治疗组为94.74%,对照组为78.95%,2组比较,差异有统计学意义(P<0.05)。2组血清hs-CRP、TNF-α水平均较治疗前下降(P<0.05,P<0.01),且治疗组上述指标下降较对照组更显著(P<0.05)。结论:射干麻黄汤联合孟鲁司特治疗CVA患者的疗效较单纯的孟鲁司特疗效更佳,且能明显降低血清hs-CRP、TNF-α水平。
Objective: To observe the clinical efficacy of Shegan Mahuang combined with montelukast in the treatment of cough variant asthma (CVA) and its effect on serum levels of inflammatory cytokines. Methods: 76 patients with CVA were randomly divided into two groups of 38 patients. The control group was given montelukast chewable tablets orally, and the treatment group was treated with Shegan Mahuang Decoction orally on the basis of the control group. The two courses of treatment were 12 weeks. The clinical effects of two groups were observed and compared. The levels of serum hs-CRP and TNF-α were detected before and after treatment. Results: The total effective rate was 94.74% in the treatment group and 78.95% in the control group. There was significant difference between the two groups (P <0.05). The levels of serum hs-CRP and TNF-α in the two groups were lower than those before treatment (P <0.05, P <0.01), and the above indexes in the treatment group decreased more significantly than those in the control group (P <0.05). Conclusion: Shegan Mahuang combined with montelukast in the treatment of CVA patients with better efficacy than montelukast, and can significantly reduce the serum hs-CRP, TNF-α levels.